Related Experiment Video

Updated: Mar 12, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.7K

[Sacubitril / Valsartan in patients with diabetes and heart failure]

Vincent Matthias Brandenburg, Hans-Peter Brunner-La Rocca, Nikolaus Marx

    Deutsche Medizinische Wochenschrift (1946)
    |November 9, 2016
    PubMed

    Insights

    Sacubitril/valsartan effectively reduces heart failure hospitalizations and mortality in patients with heart failure with reduced ejection fraction (HFREF). This treatment is also a viable option for diabetic HFREF patients, despite concerns about disease interactions.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Diabetology

    Background:

    • Sacubitril/valsartan is recommended for symptomatic heart failure with reduced ejection fraction (HFREF) patients.
    • A significant overlap exists between HFREF and diabetes mellitus.
    • Concerns have been raised regarding potential interactions between diabetes and sacubitril/valsartan efficacy.

    Purpose of the Study:

    • To assess the efficacy of sacubitril/valsartan in HFREF patients with diabetes.
    • To discuss current evidence regarding the use of sacubitril/valsartan in this specific cohort.

    Main Methods:

    • Review of existing clinical evidence and guidelines.
    • Analysis of potential drug-disease interactions.

    Main Results:

    • Sacubitril/valsartan demonstrates efficacy in reducing heart failure hospitalizations and mortality compared to enalapril in HFREF patients.
    • Evidence suggests sacubitril/valsartan remains a treatment option for HFREF patients with diabetes.

    Conclusions:

    • Sacubitril/valsartan is a beneficial treatment for HFREF patients, including those with diabetes.
    • Diabetic cardiomyopathy should be recognized as a distinct clinical entity.

    More Related Videos

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    4.3K

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.3K
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    455
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    1.1K
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    1.1K
    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    2.9K
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    1.7K